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Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in
Patients With ST-Segment–Elevation Myocardial Infarction
Antonio Abbate, MD, PhD; Cory R. Trankle, MD; Leo F. Buckley, PharmD; Michael J. Lipinski, MD, PhD; Darryn Appleton, MD;
Dinesh Kadariya, MD; Justin M. Canada, PhD; Salvatore Carbone, PhD; Charlotte S. Roberts, NP; Nayef Abouzaki, MD;
Ryan Melchior, DO; Sanah Christopher, MD; Jeremy Turlington, MD; George Mueller, DO; James Garnett, MD; Christopher Thomas, MD;
Roshanak Markley, MD; George F. Wohlford, PharmD; Laura Puckett, RN; Horacio Medina de Chazal, MD; Juan G. Chiabrando, MD;
Edoardo Bressi, MD; Marco Giuseppe Del Buono, MD; Aaron Schatz, MD; Chau Vo, MD; Dave L. Dixon, PharmD;
Giuseppe G. Biondi-Zoccai, MD, MStat; Michael C. Kontos, MD; Benjamin W. Van Tassell, PharmD
Background-—ST-segment–elevation myocardial infarction is associated with an intense acute inflammatory response and risk of
heart failure. We tested whether interleukin-1 blockade with anakinra significantly reduced the area under the curve for hsCRP
(high sensitivity C-reactive protein) levels during the first 14 days in patients with ST-segment–elevation myocardial infarction
(VCUART3 [Virginia Commonwealth University Anakinra Remodeling Trial 3]).
Methods and Results-—We conducted a randomized, placebo-controlled, double-blind, clinical trial in 99 patients with ST-
segment–elevation myocardial infarction in which patients were assigned to 2 weeks treatment with anakinra once daily (N=33),
anakinra twice daily (N=31), or placebo (N=35). hsCRP area under the curve was significantly lower in patients receiving anakinra
versus placebo (median, 67 [interquartile range, 39–120] versus 214 [interquartile range, 131–394] mgday/L; P<0.001), without
significant differences between the anakinra arms. No significant differences were found between anakinra and placebo groups in
the interval changes in left ventricular end-systolic volume (median, 1.4 [interquartile range, 9.8 to 9.8] versus 3.9 [interquartile
range, 15.4 to 1.4] mL; P=0.21) or left ventricular ejection fraction (median, 3.9% [interquartile range, 1.6% to 10.2%] versus
2.7% [interquartile range, 1.8% to 9.3%]; P=0.61) at 12 months. The incidence of death or new-onset heart failure or of death and
hospitalization for heart failure was significantly lower with anakinra versus placebo (9.4% versus 25.7% [P=0.046] and 0% versus
11.4% [P=0.011], respectively), without difference between the anakinra arms. The incidence of serious infection was not different
between anakinra and placebo groups (14% versus 14%; P=0.98). Injection site reactions occurred more frequently in patients
receiving anakinra (22%) versus placebo (3%; P=0.016).
Conclusions-—In patients presenting with ST-segment–elevation myocardial infarction, interleukin-1 blockade with anakinra
significantly reduces the systemic inflammatory response compared with placebo.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identifier: NCT01950299. ( J Am Heart Assoc. 2020;9:
e014941. DOI: 10.1161/JAHA.119.014941.)
Key Words: acute myocardial infarction • interleukin-1 • heart failure • ST-segment–elevation myocardial infarction
S T-segment–elevation myocardial infarction (STEMI)remains a major cause of morbidity and mortality world-
wide. Despite considerable advances in STEMI treatment, up to
30% of survivors develop heart failure (HF) and 10% are
hospitalized for HF within 1 year.1–4 This observation suggests
that the current treatment paradigm misses ≥1 key pathophys-
iologic mechanisms. A close interplay exists between inflam-
mation, healing after STEMI, and progression to HF. Acute
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myocardial ischemia and infarction initiate an intense inflam-
matory response.5 The degree of the inflammatory response
in STEMI is a strong predictor of adverse cardiac remodeling
independent of infarct size.5,6 Likewise, in patients with
STEMI, the intensity of the inflammatory response, reflected
in levels of circulating biomarkers, predicts adverse cardiac
remodeling, HF, and death.7 Modulation of the inflammatory
response, therefore, represents a potential target for inter-
vention. Although many previous attempts to target inflam-
mation have failed,5 interleukin-1 blockade is a novel and
substantially different approach to modulating the inflamma-
tory response.8 Preclinical studies have shown that anakinra,
a recombinant interleukin-1 receptor antagonist, improves
myocardial healing, preventing additional cardiomyocyte loss,
adverse remodeling, and HF in experimental myocardial
infarction.9 Two pilot clinical trials showed preliminary safety
and feasibility of treatment with recombinant interleukin-1
receptor antagonist, anakinra, in STEMI (VCUART [Virginia
Commonwealth University Anakinra Remodeling Trial]10 and
VCUART211,12). Moreover, the CANTOS (Canakinumab
Atherothrombosis Outcome Trial) showed prevention of
recurrent ischemic events and of hospitalizations for HF in
patients with prior myocardial infarction treated with
canakinumab, an interleukin-1b blocking antibody.13,14
The objective of this study was to determine whether
anakinra, 100 mg once daily (standard dose) or twice daily
(high dose), significantly reduced systemic inflammation
(versus placebo) in patients with STEMI (primary end point)
and whether this treatment resulted in better preservation of
left ventricular (LV) systolic function and/or reduced inci-
dence of HF events (secondary end points).
Methods
The study design and results of the study are posted online on
https://clinicaltrials.gov/ct2/show/NCT01950299.
Trial Design
The VCUART3 was a phase 2, multicenter, double-blinded,
randomized, placebo-controlled clinical trial comparing ana-
kinra, 100 mg once daily (standard dose), alternated with
placebo, once daily, every 12 hours, 100 mg twice daily (high
dose), or placebo twice daily (in 1:1:1 ratio). The study design
has been previously published.15 The trial protocol (available
online) and all subsequent amendments received approval by
the local Institutional Review Boards.
Screening and Enrollment
We screened consecutive patients, aged ≥21 years, who
presented to the hospital with acute STEMI and underwent
urgent coronary angiography within 12 hours of symptom
onset at the Virginia Commonwealth University (VCU) Health
(Richmond, VA), Virginia Cardiovascular Specialists (Rich-
mond, VA), or Medstar Washington Hospital Center (Wash-
ington, DC). All subjects provided written informed consent in
accordance with the local Institutional Review Board. Patients
were excluded from the study if they had contraindications to
treatment with anakinra, chronic inflammatory or infectious
disease, or preexisting structural or functional severe cardiac
abnormalities (Table S1 includes a complete list of inclusion
and exclusion criteria).
Randomization and Masking
Anakinra and identical matching placebo syringes were handled
by the investigational pharmacy at the coordinating center
(VCU). A randomization log was prepared and maintained at the
investigational pharmacy at VCU. The syringes were sequen-
tially numbered from 1 to 28 to maintain allocation conceal-
ment, and patients were instructed to inject the syringes
sequentially so to alternate odd-numbered syringes in the
morning and even-numbered syringes in the evening. The
investigational drug was prepared at VCU and shipped to the
other centers in blocks of 5.
Investigational Treatment
Patients were randomly assigned to receive anakinra, 100 mg
once daily (standard dose), alternating with placebo, once daily
every 12 hours for 14 days; anakinra, 100 mg twice daily, every
12 hours (high dose) for 14 days; or placebo twice daily every
12 hours for 14 days, with the first dose administered within
12 hours of coronary angiography. Patients in the study received
guideline-based medical treatments, as indicated. Compliance
was defined as >80% of prescribed doses of investigational drug.
Laboratory Analysis and Biomarkers
Blood samples were used for a complete blood cell count with
differential, comprehensive metabolic profile, and plasma
Clinical Perspective
What Is New?
• Interleukin-1 blockade significantly reduced the acute
inflammatory response in patients with ST-segment–eleva-
tion myocardial infarction.
• This reduction in inflammatory signaling was accompanied
by significant reductions in new-onset heart failure and
hospitalization for heart failure.
What Are the Clinical Implications?
• Targeted anti-inflammatory treatment with interleukin-1
blockers may be a novel approach to reduce the risk of heart
failure after ST-segment–elevation myocardial infarction.
DOI: 10.1161/JAHA.119.014941 Journal of the American Heart Association 2
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levels of hsCRP (high sensitivity C-reactive protein) (True
Health Diagnostics, Richmond, VA). All study personnel were
kept blinded to hsCRP levels.
Creatine kinase myocardial band (CK-MB) levels were
determined by direct chemiluminescent technology every
6 hours starting immediately after percutaneous coronary
intervention until peak, according to the local clinical
standard. We estimated infarct size on the basis of the
time-concentration area under the curve (AUC) of CK-MB.16,17
CK-MB peak value was defined as the maximal CK-MB level
measured during hospitalization. For patients with <6
recorded CK-MB measurements, we estimated AUC for CK-
MB by a validated log-normal model incorporating the
admission CK-MB level, the CK-MB peak level, and the time
to CK-MB peak to reconstruct the typical time course of CK-
MB curve.16,17 The time to CK-MB peak, as a measure of
duration of myocardial injury, was considered as the time
between the initial onset of symptoms (chest pain per patient
report) and the CK-MB peak level.
Doppler Echocardiography
Subjects underwent a transthoracic Doppler echocardiogram
within 24 hours of enrollment and at 1-year follow-up, as part
of their clinical care and as previously described.10,11,15
Paired measurements of LV end-diastolic and end-systolic
volumes and calculation of LV ejection fraction occurred off-
line at the end of the study by a core laboratory with 2
separate operators blinded to group allocations. The average
of the 2 measurements was used for measures differing
≤10%, whereas those with >10% difference were rereviewed
by a third operator and discussed to achieve consensus.
Primary and Secondary End Points
The primary end point was the AUC for hsCRP, measured at
baseline, 72 hours, and day 14. hsCRP is an established
prognostic marker in STEMI that reflects systemic interleukin-1
activity.18 Measuring AUC for hsCRP allowed for integration of
measurements across multiple time points to more accurately
quantify the acute inflammatory response. The primary end
point analysis compared both anakinra groups with placebo (P
for significance set at <0.05), followed by a comparison of the
anakinra, 100 mg twice daily, group with the placebo group and
the anakinra, 100 mg daily, group with the placebo group,
separately (P for significance set at <0.025).
Secondary end points included interval changes in LV end-
systolic volume and ejection fraction between baseline and
12 months and the incidence of HF. An independent
committee composed of physicians specializing in internal
medicine, cardiology, or emergency medicine, who were
blinded to treatment allocation and to hsCRP data and not
involved in the conduct of the study procedures, adjudicated
all events (Protocol). Prespecified HF end points included the
combined incidence of death and new onset of HF (defined as
hospitalization for HF or need for a new initiation of a loop
diuretic in the appropriate clinical setting; D+HF) and the
composite of all-cause death and hospitalization for HF
(D+HHF), as specified in a consensus document on the
definition of HF end points in STEMI trials.19 Additional
adjudicated events included recurrent myocardial infarction,
urgent revascularization, and severe infections.
Safety Assessment
All patients underwent a complete physical examination and
clinical evaluation at each visit. A Data and Safety Monitoring
Board, composed of cardiologists, a general internal medicine
specialist, and an infectious disease specialist, reviewed study
progress and safety data every 6 months (Protocol).
Sample Size and Statistical Analysis
The sample size for this study was calculated on the basis of
the primary outcome of comparing hsCRP-AUC with anakinra
(both groups) versus placebo, to be followed (if significant) by
an analysis of each anakinra group (standard and high dose)
versus placebo. Given an expected hsCRP-AUC of
350250 mgday/L for placebo-treated patients with STEMI
and 175150 mgday/L for anakinra (standard dose), 33
patients per group would provide >99% power (a=0.05) to
detect a difference versus placebo and 85% power (2-tailed a
0.025 considering multiple testing) to detect a further 50%
reduction in the anakinra (high dose) (estimated AUC for
hsCRP of 8875 mgday/L) versus anakinra (standard dose).
A 20% loss to follow-up or withdrawal was expected to retain
>80% power for all analyses. No missing data imputation was
used.
For statistical analysis, all values are reported as the
median and interquartile range for potential deviation from
gaussian distribution. All analyses were performed on an
intention-to-treat basis without imputation for missing data.
The differences between treatment groups were computed
using the Wilcoxon or Kruskal-Wallis rank-sum test for 2
groups (anakinra [both groups] versus placebo) or 3 groups,
respectively, for continuous variables. The differences in
interval changes between the treatments were compared
using random-effect ANOVA for repeated measures to analyze
the effects of time and group allocation. Unadjusted P values
are reported throughout, with statistical significance set at
the 2-tailed P of 0.05 for the comparison of both anakinra
groups versus placebo and of 0.025 for analysis of each dose
group versus placebo. Kaplan-Meier curves for survival free of
HF events between anakinra (combined) and placebo were
DOI: 10.1161/JAHA.119.014941 Journal of the American Heart Association 3
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constructed and compared using the log-rank (Mantel-Cox)
test. The v2 or Fisher exact tests were used for discrete
variables. All analyses were completed using the Statistical
Package for Social Sciences, version 24.0 (SPSS, Chicago, IL).
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
Results
Screening and Randomization
Between July 2014 and December 2017, 311 patients were
screened and 99 were randomized to anakinra once daily
(standard dose; N=33 [33%]), anakinra twice daily (high dose;
N=31 [31%]), or placebo (N=35 [35%]). The main reasons for
exclusion were patient preference (N=53), inability to provide
consent (N=39), active or chronic infection (N=27), or active or
recent cancer (N=23; Figure 1). All 99 patients (100%) received
at least 1 dose of investigational drug, and 77 (78%) had
complete biomarker data available for baseline, in-hospital, and
2-week follow-up, allowing for the assessment of the primary
end point of hsCRP-AUC (Figure 1). Clinical follow-up was
available for all 99 subjects (100%), ranging from 3 to 365 days,
with a median follow-up duration of 365 (interquartile range,
287–365) days, with 71 (72%) with 365 days of follow-up and
87 (88%) with >180 days of follow-up.
Characteristics of the Patients
Table 1 summarizes the clinical and demographic character-
istics of the patients. Guideline-directed therapies at time of
enrollment and at the end of the study are shown in Table S2.
There were no clinically meaningful differences between the
groups. The estimated infarct size using the AUC for CK-MB
was not statistically different comparing the different groups
(Table 1). The number of patients who completed all 14 days
of treatment was not different between the groups (24 [73%],
27 [87%], and 24 [69%] for anakinra once daily, anakinra twice
daily, and placebo, respectively; P=0.19).
AUC of hsCRPDuring the First 14 Days After STEMI
The hsCRP-AUC values during the first 14 dayswere available in
22 (67%), 27 (87%), and 28 (80%) of the anakinra once daily,
anakinra twice daily, and placebo groups, respectively, without
significant difference in the incidence of missing data between
groups (P=0.15 comparing the 3 groups, and P=0.80 comparing
pooled anakinra group versus placebo). When compared with
placebo, the hsCRP-AUC value for the first 14 days was
significantly lower in the pooled anakinra group (both doses
combined) versus the placebo group (median, 67 [interquartile
range, 39–120] versus 214 [interquartile range, 131–394]
mgday/L; P<0.001; Figure 2, Figure S1). Each anakinra arm
analyzed individually versus placebo significantly reduced
hsCRP-AUC (P<0.001) without significant differences between
the 2 anakinra arms (median, 60 [interquartile range, 24–139]
versus 86 [interquartile range, 43–123] mgday/L, for once and
twice daily anakinra, respectively; P=0.41; Figure 2, Figure S1).
The most common reason for missing data was related to lack
of blood sample at 72 hours or discharge.
Effects on LV Dimensions and Systolic Function
Paired echocardiography studies were available in 63 of 99
patients (64%) at a median of 362 days (interquartile range,
336–375 days) after the baseline study: 24 of 35 (69%)
placebo patients and 39 of 64 (60%) anakinra patients (both
doses combined). Table S3 shows the characteristics of the
subjects with paired echocardiographic data. Baseline LV end-
diastolic volume, LV end-systolic volume, stroke volume, and
LV ejection fraction were not significantly different comparing
placebo and anakinra (all P>0.05). No significant differences
were found between anakinra and placebo groups in the
interval changes in LV end-systolic volume (median, 1.4
[interquartile range, 9.8 to 9.8] versus 3.9 [interquartile
311 patients were screened between 
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Figure 1. Enrollment, randomization, and follow-up. AUC indi-
cates area under the curve; CKD, chronic kidney disease; hsCRP,
high-sensitivity C-reactive protein; HF, heart failure; PCI, percuta-
neous coronary intervention.
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range, 15.4 to 1.4] mL; P=0.21) or LV ejection fraction
(median, 3.9% [interquartile range, 1.6% to 10.2%] versus
2.7% [interquartile range, 1.8% to 9.3%]; P=0.61).
Effects on Clinical Events
There was 1 death (3%) in the placebo group and none in the
anakinra group (Table 2). Compared with placebo, treatment
with anakinra was associated with a significant reduction
versus placebo in the incidence of the composite end point of
all-cause death and new-onset or worsening HF (6/64 [9.4%]
versus 9/35 [25.7%]; log-rank v2=3.995; P=0.046), as well as
a reduction in the composite end point of all-cause death and
hospitalization for HF (0/64 [0%] versus 4/35 [11.4%]; log-
rank v2=6.516; P=0.014), without any significant difference
between the 2 anakinra arms (Table 2, Figure 3, Figure S2).
There was no difference in the composite end point of
death, recurrent myocardial infarction, or urgent
Table 1. Characteristics of the Patients at Baseline
Characteristics Anakinra, Once Daily (N=33) Anakinra, Twice Daily (N=31) Placebo (N=35)
Age, y 53 (49–62) 55 (45–61) 56 (51–65)
Female sex 9 (27) 5 (16) 5 (14)
White/black/Hispanic/other 19:12:2:3 17:9:2:3 21:6:3:5
Symptom onset to PCI time, min 210 (128–280) 145 (88–435) 180 (130–347)
Symptom onset to investigational
drug administration, min
509 (405–644) 450 (300–745) 529 (403–716)
Fibrinolytic use before PCI 1 (3) 4 (13) 3 (9)
Culprit vessel
LAD occlusion 13 (39) 13 (42) 11 (30)
RCA occlusion 12 (36) 13 (42) 18 (50)
LCX occlusion 7 (21) 5 (16) 6 (17)
SVG occlusion 1 (3) 0 1 (3)
TIMI flow grade 0/1 pre-PCI 30 (91) 27 (87) 25 (71)
TIMI flow grade 3 post-PCI 33 (100) 31 (100) 35 (100)
PCI type
Primary PCI 32 (97) 27 (87) 32 (91)
PCI after fibrinolysis 1 (3) 4 (13) 3 (9)
Coronary stent implantation 28 (85) 30 (97) 35 (100)
Use of drug-eluting stent 19 (57) 25 (81) 30 (86)
Use of thrombectomy 6 (18) 4 (13) 6 (17)
Use of a P2Y12 inhibitor 33 (100) 31 (100) 35 (100)
Clopidogrel 5 (15) 4 (13) 7 (20)
Prasugrel 10 (30) 12 (39) 12 (34)
Ticagrelor 18 (55) 15 (48) 16 (46)
Initial CK-MB level, ng/mL 5 (2–21) 11 (3–58) 7 (2–28)
Peak CK-MB level, ng/mL 100 (30–205) 134 (80–282) 93 (36–252)
CK-MB AUC at 14 d, ng/mL*d 2054 (957–3370) 3051 (1493–4694) 2351 (765–4668)
Time to peak, min 493 (321–740) 450 (343–603) 446 (281–623)
Previous diagnosis of CAD 6 (18) 8 (26) 7 (20)
Diabetes mellitus 6 (18) 9 (29) 15 (43)
Systemic arterial hypertension 13 (39) 20 (64) 23 (66)
LVEF (initial assessment), % 51 (43–58) 48 (43–58) 53 (42–57)
Data are presented as number (percentage) or median (interquartile range) for categorical or continuous variables, respectively. AUC indicates area under the curve; CAD, coronary artery
disease; CK-MB, creatine kinase myocardial band; LAD, left anterior descending artery; LCX, left circumflex artery; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary
intervention; RCA, right coronary artery; SVG, saphenous venous graft; TIMI, Thrombolysis in Myocardial Infarction.
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revascularization: 6 in the anakinra group (9%) and 5 (14%) in
placebo group (P>0.05; Table 2, Figure 3).
Treatment with anakinra was well tolerated, with no serious
unanticipated adverse events. Nine patients in the anakinra
group (14%) and 5 in the placebo group (14%; P=0.98)
experienced a serious infection requiring prescription of an
antimicrobial drug, all considered to be unrelated to the
investigational treatment (Table 2). Injection site reactions
were significantly more common in the anakinra group than in
placebo (16/64 [22%] versus 1/35 [3%]; P=0.016), leading to
early interruption of treatment in 6 anakinra-treated patients
(9%) and 1 placebo-treated patient (3%; P=0.419). There was no
significant difference in any of the other end points comparing
anakinra, once daily, with anakinra, twice daily (Table 2).
Sensitivity Per-Protocol Analysis
We performed a per-protocol analysis in which subjects were
analyzed on the basis of treatment received rather than
treatment assigned when we found, discovered during the
study closure procedures for one of secondary sites, that 3
patients received a treatment different than originally
assigned. When we analyzed per protocol comparing anakinra
combined (N=65) versus placebo (N=34), the significance in
hsCRP-AUC and HF events (D+HF and D+HHF) was confirmed
(P<0.001, P=0.032, and P=0.007, respectively).
Additional Exploratory Analysis on LV
Performance
During the recording of the Doppler echocardiogram, using
noninvasive 2-dimensional–derived LV volumes, measures of
arterial blood pressure, and Doppler-derived estimates of LV
pressure, we calculated also LV stroke volume and stroke work
(stroke work=stroke volume*[mean arterial pressure – left
ventricular end diastolic pressure]),20 surrogates for LV perfor-
mance.21 Compared with placebo, anakinra led to a significant
improvement in stroke volume (P=0.001 versus baseline and
P=0.027 for time9group interaction versus placebo) and stroke
work (P=0.001 versus baseline and P=0.004 for time9group
interaction versus placebo) (Figure S3).
Discussion
The results of this phase 2 clinical trial support the safety of
standard and high-dose anakinra in patients with STEMI and
demonstrate that either dose of anakinra blunts the acute
inflammatory response, as measured by the hsCRP-AUC at
14 days. The degree of hsCRP plasma elevation predicts in-
hospital mortality and long-term incidence of HF in patients
with STEMI.3,5–7,17,18 The strong reduction in hsCRP levels
with anakinra, at both standard and high dose, confirms prior
findings of enhanced interleukin-1 activity in patients with
STEMI.8–12 The lack of differences between standard and
high-dose anakinra suggests that the standard daily dose is
sufficient to block the interleukin-1 receptor and modulate the
inflammatory response in STEMI.
Consistent with what was seen in preclinical experimental
models,8,9 the benefits of anakinra appear to be independent of
difference of infarct size, supporting an effect of interleukin-1
blockade on the healing of the myocardium after acute
myocardial infarction. We explored the effects of anakinra on
interval changes in LV dimensions and function at 12 months.
Adverse remodeling is considered to be a primary substrate for
HF complicating STEMI3,4; however, data from this study show
minimal changes in LV volumes and systolic function among
placebo- and anakinra-treated patients. These data suggest
that current strategies of prompt reperfusion and early
neurohormonal blockade are sufficient to suppress adverse
cardiac remodeling after STEMI. Despite these advances in
treatment and the reduction in adverse remodeling, the
incidence of subsequent new or worsening HF after STEMI
remains unacceptably high, affecting up to 30% of patients at 1
year,1,2 which may imply an additional pathway for progression
to HF independent of traditional measures of cardiac remod-
eling. In an exploratory analysis, we show that patients treated
with anakinra tend to improve LV performance (stroke volume
and stroke work21) beyond what is seen in placebo. The role of
interleukin-1 in inhibiting cardiac contractility is well known
from experimental studies in cells and animals.8 Previous
studies have shown improvement in systolic function with
interleukin-1 blockade in patients with systolic HF and asso-
ciated improvement in cardiorespiratory fitness.20,22–25
Figure 2. Effects of anakinra on hsCRP (high-sensitivity C-reactive
protein). Anakinra, once daily or twice daily, significantly reduced
the area under the curve for hsCRP at 14 days (shaded areas)
(P<0.001 for each anakinra group vs placebo, and P<0.001 for
anakinra groups combined vs placebo). We found no significant
difference between the once-daily and twice-daily anakinra reg-
imens (P=0.41). Data are presented as median and interquartile
range.
DOI: 10.1161/JAHA.119.014941 Journal of the American Heart Association 6
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Although not powered to detect differences in clinical
outcomes, the prespecified analysis of HF outcomes showed a
significantly lower incidence of HF hospitalizations and of new
or worsening HF with anakinra versus placebo. The results of
the VCUART3 are consistent with the findings of the prior pilot
feasibility VCUART and VCUART210,11 that enrolled a total 40
patients with STEMI and demonstrated a nominally lower
incidence of HF at 3 months (5% versus 30%; P=0.035) that
persisted at long-term follow-up.10–12 The results of the
VCUART3 are also in agreement with the analysis of 10 061
patients in the CANTOS clinical trial of canakinumab, an
interleukin-1b blocking antibody, in stable patients with prior
myocardial infarction, in whom canakinumab provided a
significant reduction in hsCRP and a dose-dependent reduc-
tion in hospitalizations for HF.13,14
Anakinra was also studied in the MRC-ILA Heart clinical
trial of 182 patients with non–ST-segment–elevation acute
coronary syndrome showing a similar reduction in the hsCRP
values with 14 days of once-daily anakinra treatment,26 but
no data on the incidence of HF were provided. In contrast with
the MRC-ILA Heart trial,26 however, treatment with anakinra
in this study appeared to have no effect on recurrent ischemic
events, whereas an unexpected, and unexplained, excess of
late recurrent ischemic events were seen in the MRC-ILA
Heart trial, raising the concern that 2-week treatment with
anakinra was associated with an unexpected untoward late
deleterious effect, possibly because of a rebound inflamma-
tory mechanism. Reassuringly, no rebound, or excess, adverse
events were seen in the current study, nor in other studies of
anakinra used to treat patients with HF.10–12,25 Moreover, the












Death 0 0 1 (3) 0.40 0 0.17
Death or hospitalization for heart failure 0 0 4 (11) 0.022* 0 0.014*
Death or new-onset or worsening heart failure
(including outpatient and hospitalization)
3 (9) 3 (10) 9 (26) 0.09 6 (9) 0.041*
Death, recurrent acute myocardial infarction,
or urgent revascularization
5 (15) 1 (3) 5 (14) 0.24 6 (9) 0.51
Death or stroke 1 (3) 1 (3) 1 (3) 0.99 2 (3) 0.95
Sepsis or serious infection 3 (9) 6 (19) 5 (14) 0.24 9 (14) 0.98
Death or serious infections 3 (9) 6 (19) 5 (14) 0.24 9 (14) 0.98
Injection site reactions 6 (18) 8 (26) 1 (3) 0.029* 14 (22) 0.016*
Injection site reaction leading to discontinuation 3 (9) 2 (6) 1 (3) 0.56 6 (9) 0.42
Data are presented as number (percentage). P values reported for v2 or Fisher exact test.
*P<0.05.
















































































Figure 3. Effects of anakinra on heart failure clinical events. Anakinra-treated patients had a significantly lower in incidence of heart
failure related clinical events than placebo (Log-rank Mantel-Cox test). Left, a composite end point of new onset heart failure or death.
Middle, a composite end point of hospitalization for heart failure or death. Right, a composite of ischemic events (death, recurrent AMI, or
urgent revascularization).
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primary analysis of CANTOS13 showed a significant 15%
reduction in the composite outcome of myocardial infarction,
stroke, or cardiovascular death in patients treated with
canakinumab that was driven by a 20% reduction in recurrent
myocardial infarction. A significant reduction in atherothrom-
botic complications was also seen in the COLCOT (Cardio-
vascular Outcome Trial)27 in patients with recent myocardial
infarction treated with colchicine, a small molecule able to
interfere with the processing and release of interleukin-1b,
further supporting the beneficial role of interleukin-1 blockade
in acute coronary syndromes.
Study Limitations
Themajor limitations of this phase 2 study are the small sample
size and the missing data. Despite these limitations, the
statistical significance in the reduction in hsCRP levels is strong,
and it paired with a favorable safety profile of the drug. The
preliminary signal for reduced incidence of new or worsening
HF, on the other hand, requires confirmation and opens the way
to a new therapeutic strategy to be further tested in phase 3
clinical trials. Interleukin-1 blockade may represent the first
targeted anti-inflammatory strategy treatment to prevent and
treat HF in patients with STEMI. Confirmatory phase 2B/3
clinical trials are needed. A slight, not statistically significant,
imbalance in the number of patients with diabetes mellitus is
noted between groups; nevertheless, the effects of anakinra on
AUC for hsCRP appeared to be independent of diabetesmellitus
status (data not shown).
Conclusions
Among patients with STEMI, interleukin-1 blockade with
anakinra significantly reduces the systemic inflammatory
response compared with placebo, without any significant
difference between standard or high-dose regimens. Prespec-
ified analyses on clinical end points observed a reduced
incidence of HF and reduced HF hospitalizations, supporting
the potential clinical benefit of interleukin-1 blockade in
patients with acute myocardial infarction.
Acknowledgments
Swedish Orphan Biovitrum LLC (Stockholm, Sweden) has provided
study medication (anakinra) and matching placebo free of cost, but
had no role in the study design, conduct, analysis, or reporting.
Sources of Funding
The study is supported by a grant from the National Institutes of
Health (1R34HL121402-01) to Dr Abbate and Dr Van Tassell.
Disclosures
Dr Abbate and Dr Van Tassell have served as consultants to
Swedish Orphan Biovitrum LLC. The remaining authors have
no disclosures to report.
References
1. Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D’Agostino RB,
Levy D, Kannel WB, Vasan RS. Long-term trends in the incidence of heart
failure after myocardial infarction. Circulation. 2008;118:2057–2062.
2. Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA.
Declining in-hospital mortality and increasing heart failure incidence in elderly
patients with first myocardial infarction. J Am Coll Cardiol. 2009;53:13–20.
3. Chen J, Hsieh AF, Dharmarajan K, Masoudi FA, Krumholz HM. National trends
in heart failure hospitalisation after acute myocardial infarction for Medicare
beneficiaries: 1998-2010. Circulation. 2013;128:2577–2584.
4. Cung TT, Morel O, Cayla G, Rioufol G, Garcia-Dorado D, Angoulvant D,
Bonnefoy-Cudraz E, Guerin P, Elbaz M, Delarche N, Coste P, Vanzetto G, Metge
M, Aupetit JF, Jouve B, Motreff P, Tron C, Labeque JN, Steg PG, Cottin Y, Range
G, Clerc J, Claeys MJ, Coussement P, Prunier F, Moulin F, Roth O, Belle L,
Dubois P, Barragan P, Gilard M, Piot C, Colin P, De Poli F, Morice MC, Ider O,
Dubois-Rande JL, Unterseeh T, Le Breton H, Beard T, Blanchard D, Grollier G,
Malquarti V, Staat P, Sudre A, Elmer E, Hansson MJ, Bergerot C, Boussaha I,
Jossan C, Derumeaux G, Mewton N, Ovize M. Cyclosporine before PCI in
patients with acute myocardial infarction. N Engl J Med. 2015;373:1021–
1031.
5. Seropian IM, Toldo S, Van Tassell BW, Abbate A. Anti-inflammatory strategies
for ventricular remodeling following ST-segment elevation acute myocardial
infarction. J Am Coll Cardiol. 2014;63:1593–1603.
6. Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction.
Nat Rev Cardiol. 2018;15:203–214.
7. Seropian IM, Sonnino C, Van Tassell BW, Biasucci LM, Abbate A. Inflammatory
markers in ST-elevation acute myocardial infarction. Eur Heart J Acute
Cardiovasc Care. 2016;5:382–395.
8. Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a
clinical update. Eur Heart J. 2018;39:2063–2069.
9. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, Biondi-Zoccai GG,
Houser JE, Qureshi IZ, Ownby ED, Gustini E, Biasucci LM, Severino A,
Capogrossi MC, Vetrovec GW, Crea F, Baldi A, Kukreja RC, Dobrina A.
Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits
apoptosis in experimental acute myocardial infarction. Circulation.
2008;117:2670–2683.
10. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R,
Roach LM, Arena RA, Roberts CS, Varma A, Gelwix CC, Salloum FN, Hastillo A,
Dinarello CA, Vetrovec GW; VCU-ART Investigators. Interleukin-1 blockade
with anakinra to prevent adverse cardiac remodeling after acute myocardial
infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-
ART] Pilot Study). Am J Cardiol. 2010;105:1371–1377.
11. Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman
DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR,
Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, Vetrovec GW.
Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling
and heart failure after acute myocardial infarction. Am J Cardiol.
2013;111:1394–1400.
12. Abbate A, Kontos MC, Abouzaki NA, Melchior RD, Thomas C, Van Tassell BW,
Oddi C, Carbone S, Trankle CR, Roberts CS, Mueller GH, Gambill ML,
Christopher S, Markley R, Vetrovec GW, Dinarello CA, Biondi-Zoccai G.
Comparative safety of interleukin-1 blockade with anakinra in patients with ST-
segment elevation acute myocardial infarction (from the VCU-ART and VCU-
ART2 pilot studies). Am J Cardiol. 2015;115:288–292.
13. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C,
Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P,
Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L,
Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby
P, Glynn RJ; CANTOS Trial Group. Antiinflammatory therapy with canakinumab
for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.
14. Everett BM, Cornel JH, Lainscak M, Anker SD, Abbate A, Thuren T, Libby P, Glynn
RJ, Ridker PM. Anti-inflammatory therapywith canakinumab for the prevention of
hospitalisation for heart failure. Circulation. 2019;139:1289–1299.
15. Van Tassell BW, Lipinski MJ, Appleton D, Roberts CS, Kontos MC, Abouzaki N,
Melchior R, Mueller G, Garnett J, Canada J, Carbone S, Buckley LF, Wohlford G,
Kadariya D, Trankle CR, Oddi ERDLE C, Sculthorpe R, Puckett L, DeWilde C,
DOI: 10.1161/JAHA.119.014941 Journal of the American Heart Association 8


















 http://ahajournals.org by on June 5, 2020
Shah K, Angiolillo DJ, Vetrovec G, Biondi-Zoccai G, Arena R, Abbate A.
Rationale and design of the Virginia Commonwealth University-Anakinra
Remodeling Trial-3 (VCU-ART3): a randomized, placebo-controlled, double-
blinded, multicenter study. Clin Cardiol. 2018;41:1004–1008.
16. Lopes RD, Lokhnygina Y, Hasselblad V, Newby KL, Yow E, Granger CB,
Armstrong PW, Hochman JS, Mills JS, Ruzyllo W, Mahaffey KW. Methods of
creatine kinase-MB analysis to predict mortality in patients with myocardial
infarction treated with reperfusion therapy. Trials. 2013;14:123.
17. Abouzaki NA, Christopher S, Trankle C, Van Tassell BW, Carbone S, Mauro AG,
Buckley L, Toldo S, Abbate A. Inhibiting the inflammatory injury after
myocardial ischemia reperfusion with plasma-derived alpha-1 antitrypsin: a
post hoc analysis of the VCU-a1RT Study. J Cardiovasc Pharmacol.
2018;71:375–379.
18. Ørn S, Manhenke C, Ueland T, Damas JK, Mollnes TE, Edvardsen T, Aukrust P,
Dickstein K. C-reactive protein, infarct size, microvascular obstruction, and
left-ventricular remodelling following acute myocardial infarction. Eur Heart J.
2009;30:1180–1186.
19. Eapen ZJ, Tang WH, Felker GM, Hernandez AF, Mahaffey KW, Lincoff AM, Roe
MT. Defining heart failure end points in ST-segment elevation myocardial
infarction trials: integrating past experiences to chart a path forward. Circ
Cardiovasc Qual Outcomes. 2012;5:594–600.
20. Buckley LF, Carbone S, Trankle CR, Canada JM, Erdle CO, Regan JA, Viscusi
MM, Kadariya D, Billingsley H, Arena R, Abbate A, Van Tassell BW. Effect of
interleukin-1 blockade on left ventricular systolic performance and work: a
post hoc pooled analysis of 2 clinical trials. J Cardiovasc Pharmacol.
2018;72:68–70.
21. Andersen MJ, Borlaug BA. Invasive hemodynamic characterization of heart
failure with preserved ejection fraction. Heart Fail Clin. 2014;10:435–444.
22. Van Tassell BW, Abouzaki NA, Oddi Erdle C, Carbone S, Trankle CR, Melchior
RD, Turlington JS, Thurber CJ, Christopher S, Dixon DL, Fronk DT, Thomas
CS, Rose SW, Buckley LF, Dinarello CA, Biondi-Zoccai G, Abbate A.
Interleukin-1 blockade in acute decompensated heart failure: a randomized,
double-blinded, placebo-controlled pilot study. J Cardiovasc Pharmacol.
2016;67:544–551.
23. Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM, Shah
K, Canada J, Voelkel NF, Dinarello CA, Abbate A. Enhanced interleukin-1
activity contributes to exercise intolerance in patients with systolic heart
failure. PLoS One. 2012;7:e33438.
24. Trankle CR, Canada JM, Cei L, Abouzaki N, Oddi-Erdle C, Kadariya D,
Christopher S, Viscusi M, Del Buono M, Kontos MC, Arena R, Van Tassell B,
Abbate A. Usefulness of canakinumab to improve exercise capacity in patients
with long-term systolic heart failure and elevated c-reactive protein. Am J
Cardiol. 2018;122:1366–1370.
25. Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi Erdle C,
Abouzaki NA, Dixon D, Kadariya D, Christopher S, Schatz A, Regan J, Viscusi
M, Del Buono M, Melchior R, Mankad P, Lu J, Sculthorpe R, Biondi-Zoccai G,
Lesnefsky E, Arena R, Abbate A. Interleukin-1 blockade in recently
decompensated systolic heart failure: results from REDHART (Recently
Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail.
2017;10:e004373.
26. Morton AC, Rothman AM, Greenwood JP, Gunn J, Chase A, Clarke B, Hall AS,
Fox K, Foley C, Banya W, Wang D, Flather MD, Crossman DC. The effect of
interleukin-1 receptor antagonist therapy on markers of inflammation in non-
ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J.
2015;36:377–384.
27. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ,
Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W,
Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M,
Blondeau L, Orfanos A, L’Allier PL, Guertin MC, Roubille F. Efficacy and safety
and low dose colchicine after myocardial infarction. N Engl J Med. 2019. DOI:
10.1056/NEJMoa1912388. [Epub ahead of print].
DOI: 10.1161/JAHA.119.014941 Journal of the American Heart Association 9























 http://ahajournals.org by on June 5, 2020
Table S1. Inclusion and Exclusion criteria. 
Inclusion Criteria 
(Must meet all 3 inclusion criteria) 
1) Presentation to the hospital with acute STEMI defined as chest pain (or equivalent) with an onset within 12
hours and ECG evidence of ST segment elevation (>1 mm) in 2 or more anatomically contiguous leads that
is new or presumably new
2) Coronary angiography for potential intervention completed within 12 hours of symptom onset, and enrollment
in the study within 12 hours of angiography (max 24 hours from symptom onset)
3) Age > 21 years
Exclusion Criteria 
(None of the exclusion criteria should be present) 
1) Inability to give informed consent
2) Pregnancy or breastfeeding
3) Preexisting congestive heart failure (AHA/ACC class C-D, New York Heart Association III-IV)
4) Preexisting severe left ventricular dysfunction (EF<20%)
5) Preexisting severe valvular heart disease
6) Active infections (acute or chronic)
7) Recent (<14 days) or active use of immunosuppressive drugs (including but not limited to high-dose
corticosteroids [>1_mg/kg of prednisone equivalent], TNF- blockers, cyclosporine) not including NSAIDs
or corticosteroids used for IV dye allergy only)
8) Chronic auto-immune or auto-inflammatory disease (including but not limited to rheumatoid arthritis,
systemic lupus erythematosus)
9) Known active malignancy of any type, or prior diagnosis in the past 10 years
10) Anticipated need for cardiac surgery
11) Active cancer (or prior diagnosis of cancer within the past 10 years, not considering in situ or localized
carcinomas treated with surgical resection alone)
12) Neutropenia (absolute neutrophil count<1,800/mm3 [or <1,000/mm3 in African-American patients])
13) Severe impairment in renal function (estimated glomerular filtration rate <30 ml/kg*min/1.73 m2)
14) Allergy to rubber or latex
15) Allergy to products derived from Escherichia coli
STEMI=ST elevation myocardial infarction; ECG=electrocardiogram; AHA/ACC=Americxan Heart 
Association/American College of Cardiology; EF=left-ventricular ejection fraction; TNF-=tumor necrosis 
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Table S2. Guideline-directed therapy at the beginning and at the end of the follow up. 
















Aspirin (%) 35 (100%) 64 (100%) 1.0 31 (94%) 57 (95%) 0.83 
P2Y12 inhibitors (%) 35 (100%) 64 (100%) 1.0 31 (94%) 54 (90%) 0.52 
Statins (%) 34 (97%) 64 (100%) 0.35 29 (88%) 57 (95%) 0.24 
ACE-inhibitors or ARB (%) 30 (86%) 54 (84%) 0.86 26 (79%) 44 (73%) 0.62 
Mineralocorticoid receptor antagonists (%) 2 (6%) 4 (6%) 1.0 4 (12%) 6 (10%) 0.74 
-adrenergic blockers (%) 27 (91%) 56 (88%) 0.74 31 (94%) 51 (85%) 0.32 
Antiarrhythmics (%) 3 (9%) 2 (3%) 0.34 2 (6%) 1 (2%) 1.00 
Long-acting Nitrates (%) 3 (9%) 2 (3%) 0.34 2 (6%) 2 (3%) 0.61 
Diuretics (%) 5 (14%) 4 (6%) 0.27 5 (15%) 11 (18%) 0.78 
Hydralazine (%) 4 (11%) 0 0.014 4 (12%) 0 0.014 
Metformin (%) 3 (9%) 11 (17%) 0.37 5 (15%) 12 (20%) 0.78 
Insulin (%) 10 (29%) 8 (12%) 0.06 9 (27%) 8 (13%) 0.16 
Direct oral anticoagulants (%) 1 (3%) 4 (6%) 0.65 2 (6%) 2 (3%) 0.61 
Vitamin K antagonist (%) 3 (9%) 2 (3%) 0.34 2 (6%) 0 0.12 
Digoxin (%) 0 0 1.0 1 (3%) 0 0.36 
Data are presented as number and percentage. 
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Age (years) 56 [52 to 63] 55 [44 to 60] 55 [50 to 60] 0.481 
Female sex (%) 5 (28%) 4 (19%) 4 (17%) 0.662 
White / Black / Hispanic / Other 12 /6 14 / 7 17 / 7 0.942 
Previous diagnosis of CAD (%) 3 (17%) 4 (19%) 9 (38%) 0.220 
Previous diagnosis of HF (%) 0 1 (4.8%) 3 (13%) 0.242 
Diabetes mellitus (%) 4 (22%) 6 (29%) 9 (38%) 0.555 
Hypertension (%) 10 (56%) 11 (52%) 16 (68%) 0.592 
Symptoms onset to PCI time 
(min) 
205 [133 to 293] 124 [85 to 398] 182 [117 to 360] 0.621 
Symptoms to investigational drug 
administration (min) 
518 [378 to 687] 380 [270 to 670] 485 [369 to 712] 0.363 
Fibrinolytic use prior to PCI (%) 0 4 (19%) 2 (8%) 0.162 
Culprit vessel    0.544 
LAD (%) 7 (39%) 10 (48%) 7 (29%)  
RCA (%) 8 (44%) 7 (33%) 13 (54%)  
Cx (%) 2 (11%) 4 (19%) 4 (17%)  
SVG (%) 1 (6%) 0 0  
TIMI flow grade 0/1 pre-PCI (%) 18 (100%) 17 (81%) 18 (75%) 0.163 
TIMI flow grade 3 post-PCI (%) 18 (100%) 21 (100%) 24 (100%) 1 
Coronary stent implantation (%) 18 (100%) 21 (100%) 24 (100%) 1 
Use of drug eluting stent (%) 11 (61%) 17 (81%) 20 (83%) 0.204 
Use of thrombectomy (%) 2 (11%) 4 (19%) 4 (17%) 0.788 
 
Data are presented as number and percentage or median and interquartile range for categorical or 
continuous variables, respectively. 
CAD=coronary artery disease; LCX=left circumflex artery; HF=heart failure; LAD=left anterior 
descending artery; PCI=percutaneous coronary intervention; RCA=right coronary artery; 
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 Figure S1. Individual values of C-reactive protein area-under-the-curve values.  
Anakinra once daily or twice daily significantly reduced the C-reactive protein area-under-the-curve 
(CRP AUC) at 14 days (P<0.001 for all comparisons), without any significant differences between the 




 http://ahajournals.org by on June 5, 2020
2 
Figure S2. Effects of anakinra once daily and anakinra twice daily on heart failure events. 
Kaplan-Meier survival curves for anakinra once daily, anakinra twice daily, and placebo are shown for the 
composite endpoint of death or heart failure (P=0.14 between groups) and for death and hospitalization for 
heart failure (P=0.038 between groups)(Log-rank test). No significant differences were found comparing 
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Figure S3. Effects of anakinra on stroke volume and stroke work. 
Anakinra led to a significant  improvement in stroke volume (P=0.001 versus baseline and P=0.027 for 
time_x_group interaction versus placebo  [central panel]) and stroke work (P=0.001 versus baseline 
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